Patents Issued in March 6, 2003
  • Combination medicament for treatment of neoplastic diseases
    Publication number: 20030045515
    Abstract: Pharmaceutical compositions comprising, as a first anti-neoplastic drug, cyanoguanidine IKK inhibitors, and in particular compounds of formula I 1
    Type: Application
    Filed: May 21, 2002
    Publication date: March 6, 2003
    Inventors: Lise Binderup, Erik Bramm, Pernille-Julia Vig Hjarnaa, Karin Jexner Hamberg
  • Chemokine receptor antagonists and methods of use therefor
    Publication number: 20030045516
    Abstract: Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation.
    Type: Application
    Filed: August 13, 2002
    Publication date: March 6, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Jay R. Luly, Yoshisuke Nakasato, Etsuo Ohshima, Hiroki Sone, Osamu Kotera, Geraldine C. B. Harriman
  • Nonpeptide substituted spirobenzoazepines as vasopressin antagonists
    Publication number: 20030045517
    Abstract: The invention is directed to nonpeptide substituted benzodiazepines of Formula I, 1
    Type: Application
    Filed: July 2, 2001
    Publication date: March 6, 2003
    Inventors: Robert H.K. Chen, Min A. Xiang
  • Taxol enhancer compounds
    Publication number: 20030045518
    Abstract: One embodiment of the present invention is a compound represented by the Structural Formula (I): 1
    Type: Application
    Filed: July 10, 2002
    Publication date: March 6, 2003
    Applicant: Shionogi BioResearch Corp.
    Inventors: Keizo Koya, Lijun Sun, Shoujun Chen, Noriaki Tatsuta, Yaming Wu, Mitsunori Ono, Zhi-Qiang Xia
  • Novel non-imidazole compounds
    Publication number: 20030045519
    Abstract: Disclosed are novel compounds of the formula 1
    Type: Application
    Filed: October 15, 2001
    Publication date: March 6, 2003
    Inventors: Robert G. Aslanian, Neng-Yang Shih, Pauline C. Ting, Michael Y. Berlin, Stuart B. Rosenblum, Kevin D. McCormick, Wing C. Tom, Christopher W. Boyce, Pietro Mangiaracina, Mwangi W. Mutahi, John J. Piwinski
  • Tricyclic compound having spiro union
    Publication number: 20030045520
    Abstract: This invention relates to tricyclic compounds having spiro union represented by the following formula (I) or its salt which is useful as a drug, and in particular, as an inhibitor for activated blood coagulation factor X, which can be administered orally and which exhibits strong anticoagulation action.
    Type: Application
    Filed: December 27, 2001
    Publication date: March 6, 2003
    Inventors: Hidemitsu Nishida, Fumihiko Saitoh, Kousuke Harada, Ikuya Shiromizu, Takafumi Mukaihira
  • Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors
    Publication number: 20030045521
    Abstract: Sulfohydroxamic acid diarylamines and derivatives thereof; compositions made from them; and methods of using them.
    Type: Application
    Filed: September 13, 2002
    Publication date: March 6, 2003
    Inventor: Haile Tecle
  • Novel galenical form for oral administration with prolonged release of molsidomine
    Publication number: 20030045522
    Abstract: The present invention relates to a novel sustained-release oral galenical form of molsidomine for the treatment of all forms of angina attack (angina of effort, spastic angina, mixed angina). According to the invention, this novel galenical form contains a therapeutically effective amount of molsidomine or one of its active metabolites and has an in vitro dissolution rate [measured spectrophotometrically at 286 or 311 nm by the method described in the European Pharmacopoeia, 3rd edition (or USP XXIV), at 50 rpm, in 500 ml of a 0.1 N HCl medium, at 37° C.] of: 15 to 25% of molsidomine released after 1 hour, 20 to 35% of molsidomine released after 2 hours, 50 to 65% of molsidomine released after 6 hours, 75 to 95% of molsidomine released after 12 hours, >85% of molsidomine released after 18 hours and >90% of molsidomine released after 24 hours, the plasma peak of molsidomine obtained in vivo occurring 2.
    Type: Application
    Filed: October 2, 2002
    Publication date: March 6, 2003
    Inventor: Jozsef-Michel Geczy
  • Pharmaceutical compositions and methods for use
    Publication number: 20030045523
    Abstract: Pharmaceutical compositions include aryl substituted amine compounds, and in particular, carbon-linked aromatic azabicyclo compounds, and in particular, aromatic alkylene azabicyclo compounds and aromatic alkyl azabicyclo compounds.
    Type: Application
    Filed: June 4, 2002
    Publication date: March 6, 2003
    Inventors: Jeffrey Daniel Schmitt, Peter Anthony Crooks, Gary Maurice Dull
  • Alpha-2-adrenergic agonist/fatty acid compositions
    Publication number: 20030045524
    Abstract: Compositions comprising an alpha-2-adrenergic agonist component and a fatty acid component, that enhances the pharmacokinetic disposition of the therapeutic component, are disclosed. The fatty acid component may include linolenic acid and/or other fatty acids. In a one embodiment, the alpha-2-adrenergic agonist component and the fatty acid component form a complex.
    Type: Application
    Filed: May 1, 2002
    Publication date: March 6, 2003
    Inventors: David F. Woodward, Gyorgy Ambrus
  • Quinoline and quinazoline compounds useful in therapy
    Publication number: 20030045525
    Abstract: Compounds of formula I, 1
    Type: Application
    Filed: September 23, 2002
    Publication date: March 6, 2003
    Inventors: Alan John Collis, David Nathan Fox
  • Antipsychotic aminomethyl derivatives of 1,3,7,8-tetrahydro-6,9-dioxa-1,3-diaza-cyclopenta[a]-naphthalen-2-one
    Publication number: 20030045526
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: April 23, 2002
    Publication date: March 6, 2003
    Applicant: Wyeth
    Inventor: Gary P. Stack
  • 4-piperazinylindole derivatives with 5-HT6 receptor affinity
    Publication number: 20030045527
    Abstract: This invention relates to compounds which have generally 5-HT6 receptor affinity and which are represented by Formula I: 1
    Type: Application
    Filed: June 14, 2002
    Publication date: March 6, 2003
    Inventors: Andrew John Briggs, Robin Douglas Clark, Ralph New Harris, David Bruce Repke, Douglas Leslie Wren
  • Hygromycin a derivatives
    Publication number: 20030045528
    Abstract: This invention relates to compounds of the formula 1
    Type: Application
    Filed: June 1, 2001
    Publication date: March 6, 2003
    Inventors: Matthew Merrill Hayward, Michael S. Visser, Robert G. Linde, Takushi Kaneko
  • Method for specifically potentiating N-type Ca2+ channel activity
    Publication number: 20030045529
    Abstract: The present invention provides a method of specifically potentiating an N-type Ca2+ channel activity, which includes administering, to a subject, a compound of the following formula (I): 1
    Type: Application
    Filed: February 28, 2002
    Publication date: March 6, 2003
    Applicant: Shuji KANEKO
    Inventors: Shuji Kaneko, Nobuya Matsuoka
  • Preferentially substituted calcium channel blockers
    Publication number: 20030045530
    Abstract: Compounds of the formula 1
    Type: Application
    Filed: January 29, 2002
    Publication date: March 6, 2003
    Inventor: Terrance P. Snutch
  • Butenyl substituted taxanes
    Publication number: 20030045531
    Abstract: Taxane derivatives having a 3′ butenyl substituted C13 side chain.
    Type: Application
    Filed: March 29, 2002
    Publication date: March 6, 2003
    Applicant: Florida State University
    Inventors: Robert A. Holton, Ki-Byung Chai, Hossain Nadizadeh
  • Triazolo-pyrimidine derivatives as ligands for gaba receptors
    Publication number: 20030045532
    Abstract: A class of substituted or 6,7-ring fused [1, 2, 3]triazolo[1,5-&agr;]-pyrimidine derivatives, possessing an optionally substituted cycloalkyl, phenyl or heteroaryl substituent at the 3-position and an amino moiety at the 5-position, are selective ligands for GABAA receptors, in particular having high affinity for the &agr;2 and/or ◯subunit thereof, and are accordingly of benefit in the treatment and/or prevention of disorders of the central nervous system, including anxiety and convulsions.
    Type: Application
    Filed: June 14, 2002
    Publication date: March 6, 2003
    Inventors: Mark Stuart Chambers, Ian James Collins, Simon Charles Goodacre, David James Hallett, Philip Jones, Linda Elizabeth Keown, Robert James Maxey, Leslie Joseph Street
  • Phosphodiesterase 4 inhibitors
    Publication number: 20030045533
    Abstract: PDE4 inhibition is achieved by novel compounds of the Formula I: 1
    Type: Application
    Filed: February 8, 2002
    Publication date: March 6, 2003
    Applicant: MEMORY PHARMACEUTICALS CORP.
    Inventors: Ruiping Liu, Hans-Jurgen Ernst Hess, Allen Hopper, Ashok Tehim, Yajing Rong
  • Pharmaceutical combination of antiviral agents
    Publication number: 20030045534
    Abstract: In accordance with the present invention there is provided a pharmaceutical combination useful for the treatment of viral infections comprising a at least one antiviral active compound of formula (1) 1
    Type: Application
    Filed: May 16, 2002
    Publication date: March 6, 2003
    Applicant: Shire BioChem Inc.
    Inventors: Robert F. Rando, Zhengxian Gu
  • Bicyclic-substituted 4-amino-pyridopyrimidine derivatives
    Publication number: 20030045535
    Abstract: The invention relates to 6- or 7-bicyclic-substituted 4-amino-subsituted pyridopyrimidines and to pharmaceutically acceptable salts, prodrugs and hydrates thereof. The invention also relates to pharmaceutical compositions containing the compounds and to methods of treating hyperproliferative disorders abnormal cell growth in a mammal by administering the compounds.
    Type: Application
    Filed: April 12, 2002
    Publication date: March 6, 2003
    Applicant: Pfizer Inc.
    Inventors: Joel Morris, Samit K. Bhattacharya, John C. Kath
  • Compounds specific to adenosine A1 receptors and uses thereof
    Publication number: 20030045536
    Abstract: This invention pertains to compounds which specifically inhibit the adenosine A1 receptor and the use of these compounds to treat a disease associated with A1 adenosine receptors in a subject.
    Type: Application
    Filed: November 30, 2001
    Publication date: March 6, 2003
    Inventors: Arlindo L. Castelhano, Bryan McKibben, David J. Witter
  • 4-(Phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives and process for preparing the same
    Publication number: 20030045537
    Abstract: The present invention relates to 4-(phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives which inhibit tyrosine kinase of epidermal growth factor receptor (EGFR), and pharmaceutically acceptable salts, hydrates and solvates thereof, and a process for preparing the same. Since 4-(phenylamino)-[1,4]dioxano[2,3-g]quinazoline derivatives of the invention have a high solubility in water and inhibit the activity of EGFR tyrosine kinase and the growth of cancer cells, they can be practically applied in the treatment of overproliferation-associated diseases such as cancer.
    Type: Application
    Filed: March 11, 2002
    Publication date: March 6, 2003
    Inventors: Yong-Sup Lee, Ho-Koon Park, Jae-Yeol Lee, Beom-Seok Yang, Seon-Hee Seo
  • Viologen linked acridine based molecule and process for the preparation thereof
    Publication number: 20030045538
    Abstract: The present invention provides a series of novel bifunctional molecules based on viologen linked acridine, bisacridine and bisacridinium salts of the general formula 1 (1a, 1b, 1c and 1d) and or pharmaceutically acceptable derivatives thereof, which can be used as phototherapeutic and catalytic photoactivated DNA cleaving agents. These molecules are very stable and exhibit high solubility in buffer at physiological conditions. They undergo strong binding with DNA through intercalation and groove binding interactions and show remarkably high affinity for poly(dA).poly(dT) sequences. Upon photoactivation, they cleave DNA catalytically and selectively at guanine (G) sites in duplex DNA exclusively through cosensitization mechanism with a preference for 5′-G over 3′-G. They induce unusally high specificity of cleavage at G site of the AG two base bulge sequences.
    Type: Application
    Filed: February 28, 2001
    Publication date: March 6, 2003
    Applicant: COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH of India
    Inventors: Ramaiah Danaboyina, Varghese Eldho Nadukkudy, Joseph Joshy
  • Cabergoline and pramipexole: new uses and combinations
    Publication number: 20030045539
    Abstract: This invention discloses new uses and treatments involving cabergoline, pramipexole and new combinations of cabergoline plus pramipexole used to treat patients. Here we disclose the use of cabergoline or pramipexole to treat PSP and MSA. Also disclosed is a combination treatment of cabergoline and pramipexole provided concurrently to a patient in need thereof for the treatment of various central nervous system diseases and in particular for the treatment of Parkinson's Disease (PD), but also for PSP and MSA.
    Type: Application
    Filed: October 16, 2002
    Publication date: March 6, 2003
    Inventor: Baltazar Gomez-Mancilla
  • Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease
    Publication number: 20030045540
    Abstract: The invention provides compounds of Formula I: 1
    Type: Application
    Filed: June 6, 2002
    Publication date: March 6, 2003
    Inventors: Donn G. Wishka, Steven Charles Reitz, David W. Piotrowski, Vincent E. Groppi
  • GABA-Receptor modulators with NMDA-Antagonistic activity
    Publication number: 20030045541
    Abstract: The use of GABAA-receptor modulators with NMDA-antagonistic activity for the production of a pharmaceutical agent for neuroprotection and the combination of GABAA-receptor modulators with NMDA-antagonistic action and &agr;-lipoic acid or dihydro-&agr;-lipoic acid is described.
    Type: Application
    Filed: July 19, 2002
    Publication date: March 6, 2003
    Inventors: Christopher Bruckner, Rainer Dorow, Roland Neuhaus
  • Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinoline
    Publication number: 20030045542
    Abstract: Compounds of the formula: 1
    Type: Application
    Filed: August 27, 2002
    Publication date: March 6, 2003
    Applicant: Wyeth
    Inventors: Megan Tran, Gary P. Stack
  • Systems and methods for treating a mucosal surface
    Publication number: 20030045543
    Abstract: A system for treating a condition associated with a mucosal surface, the system comprising an immune response modifier (IRM) compound chosen from imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, imidazonaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, 1,2-bridged imidazoquinoline amines, and pharmaceutically acceptable salts thereof and an applicator device for applying the IRM compound to the mucosal surface. This system of IRM compounds and applicator may be used to treat conditions associated with mucosal surfaces such as cervical dysphasia and cervical intraepithelial neoplasia.
    Type: Application
    Filed: September 10, 2002
    Publication date: March 6, 2003
    Applicant: 3M Innovative Properties Company
    Inventors: John C. Hedenstrom, Michael J. Jozwiakowski, Mark Martinez, Kenneth R. Phares, Kenneth Trofatter
  • Use of chemotherapeutic agents
    Publication number: 20030045544
    Abstract: The invention relates to the use of chemotherapeutic agents for the production of a medicament for the topical and/or local treatment of diseases caused by bacteria and/or for prophylaxis in humans or animals.
    Type: Application
    Filed: June 21, 2002
    Publication date: March 6, 2003
    Inventors: Hans-Herrman Schulz, Gunther Schlimbach
  • Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
    Publication number: 20030045545
    Abstract: Thiazolo-, oxazolo- and selenazolo[4,5-c]quinolin-4-amines and analogs thereof are described including methods of manufacture and the use of novel intermediates. The compounds are immunomodulators and induce cytokine biosynthesis, including interferon and/or tumor biosynthesis, necrosis factor, and inhibit the T-helper-type 2 immune response. The compounds are further useful in the treatment of viral and neoplastic diseases.
    Type: Application
    Filed: September 12, 2002
    Publication date: March 6, 2003
    Applicant: 3M Innovative Properties Company
    Inventors: John F. Gerster, Kyle J. Lindstrom, Gregory J. Marszalek, Bryon A. Merrill, John W. Mickelson, Michael J. Rice
  • Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof
    Publication number: 20030045546
    Abstract: The present invention is directed to substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs thereof, represented by the Formula I: 1
    Type: Application
    Filed: June 10, 2002
    Publication date: March 6, 2003
    Inventors: Sui Xiong Cai, Han-Zhong Zhang, John A. Drewe, P. Sanjeeva Reddy, Shailaja Kasibhatla, Jared Daniel Kuemmerle, Kristin P. Ollis
  • Process for producing carbostyril derivatives
    Publication number: 20030045547
    Abstract: The present invention provides a process for producing carbostyril derivatives (I) which are known to be useful as medical drug such as antithrombotic agent, cerebral circulation improver, anti-inflammatory agent, antiulcer agent, etc. in a high yield and a high purity. The carbostyril derivatives (I) can be produced by reacting a carbostyril derivative (II) with a tetrazole derivative (III) in the presence of a phase transfer catalyst.
    Type: Application
    Filed: August 5, 2002
    Publication date: March 6, 2003
    Inventors: Shinji Aki, Muneaki Kurimura, Takao Nishi, Junichi Minamikawa, Michiaki Tominaga, Norihiro Fukuyama, Akihiro Yamamoto
  • Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-YL)butoxy]-3,4-dihydro-2(1H)-quinolinone
    Publication number: 20030045548
    Abstract: Polymorphs Form B, Form C, and amorphous of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, commonly known as cilostazol, have been identified. These polymorphs may be formed in pure form, in combination with each other, in combination with other polymorphs of cilostazol, or together with other pharmaceutical agents. Processes for preparing these polymorphs, and combinations of these polymorphs, as well as methods of use and unit dosages of these polymorphic forms, and their combinations, are described.
    Type: Application
    Filed: June 29, 2001
    Publication date: March 6, 2003
    Inventors: Grayson Walker Stowell, Robert R. Whittle
  • Polymorphic forms of 6-[4-(1-cyclohexyl-1h-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone
    Publication number: 20030045549
    Abstract: Polymorphs Form B, Form C, and amorphous of 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone, commonly known as cilostazol, have been identified. These polymorphs may be formed in pure form, in combination with each other, in combination with other polymorphs of cilostazol, or together with other pharmaceutical agents. Processes for preparing these polymorphs, and combinations of these polymorphs, as well as methods of use and unit dosages of these polymorphic forms, and their combinations, are described.
    Type: Application
    Filed: June 29, 2001
    Publication date: March 6, 2003
    Inventors: Grayson Walker Stowell, Robert R. Whittle
  • Bicyclic aromatic chemokine receptor ligands
    Publication number: 20030045550
    Abstract: The invention provides therapeutic and biological uses of chemokine-receptor-binding compounds (including chemokine receptor ligands such as chemokine receptor agonists or antagonists), such as naphthoic acid derivatives, including uses in the treatment of disease states mediated by chemokines. The relevant chemokine may for example be stromal cell-derived factor (SDF)-1, and the relevant chemokine receptors may for example be corresponding chemokine receptor (CXCR-4). In other aspects, the invention provides corresponding pharamaceutical compositions and therapeutic methods. In one aspect, for example, the invention provides for the use of 3-Hydroxy-2-naphthoic acid in the treatment of disease.
    Type: Application
    Filed: November 13, 2001
    Publication date: March 6, 2003
    Inventors: Geeta Saxena, Christopher R. Tudan, Ahmed Merzouk, Hassan Salari
  • Pseudopolymorph of ( - ) -cis -2-(2 -chlorophenyl) -5, 7-dihydroxy-8 [4R- ( 3S-hydroxy -1-methyl)piperidinyl ] -4H -1 -benzopyran-4-one
    Publication number: 20030045551
    Abstract: The present invention comprises a pseudopolymorph of (−)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one hydrochloride, a method of making same, a pharmaceutical composition and methods of using the pseudopolymorph.
    Type: Application
    Filed: January 16, 2001
    Publication date: March 6, 2003
    Inventors: Gary L. Bafus, Christine M. Harrison-Bowman, Gary Lee Silvey
  • Isoindole-imide compounds, compositions, and uses thereof
    Publication number: 20030045552
    Abstract: The invention relates to isoindole-imide compounds and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions comprising these isoindole-imide compounds, and methods for reducing the level of cytokines and their precursors in mammals. In particular, the invention pertains to isoindole-imide compounds that are potent inhibitors of the production of TNF-&agr; in mammals. The isoindole-imides described herein are useful for treating or preventing diseases or disorders in mammals, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; osteoporosis; and genetic, inflammatory; allergic; and autoimmune diseases.
    Type: Application
    Filed: October 5, 2001
    Publication date: March 6, 2003
    Inventors: Michael J. Robarge, Roger Shen-Chu Chen, George W. Muller, Hon-Wah Man
  • Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
    Publication number: 20030045553
    Abstract: Combination therapy comprising PPAR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.
    Type: Application
    Filed: April 3, 2002
    Publication date: March 6, 2003
    Inventors: Jacqueline C. Bussolari, Xiaoli Chen, Bruce R. Conway, Keith T. Demarest, Hamish N.M. Ross, Rafael Severino
  • Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation, therapeutic and cosmetic uses thereof
    Publication number: 20030045554
    Abstract: The invention discloses a new clause of a five membered heterocylic ring compounds of general formula 1 1
    Type: Application
    Filed: April 5, 2002
    Publication date: March 6, 2003
    Applicant: TORRENT PHARMACEUTICALS LTD.
    Inventor: Alangudi Sankaranarayanan
  • Process to chiral integrin antagonist beta-amino acid intermediate
    Publication number: 20030045555
    Abstract: The invention discloses a novel process for the preparation of enantiomerically enriched mixtures of compounds of structural formula I which are useful intermediates in the synthesis of &agr;v&bgr;3 integrin receptor antagonists.
    Type: Application
    Filed: July 17, 2002
    Publication date: March 6, 2003
    Inventors: Nelo R. Rivera, Christopher J. Welch, Yi Xiao, Nobuyoshi Yasuda
  • Aryl-N-cyanoguanidines and methods related thereto
    Publication number: 20030045556
    Abstract: Compounds, compositions and methods treating arthritic disorders such as osteoarthritis or rheumatoid arthritis, and for treating other diseases associated with altered mitochondrial function, such as cancer, psoriasis, stroke, Alzheimer's Disease and diabetes.
    Type: Application
    Filed: February 27, 2002
    Publication date: March 6, 2003
    Applicant: MitoKor
    Inventors: Soumitra S. Ghosh, Tomas R. Szabo
  • Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors
    Publication number: 20030045557
    Abstract: The invention provides 1,3,4-thiadiazoles and 1,3,4-oxadiazoles having the following Formula I: 1
    Type: Application
    Filed: October 1, 2001
    Publication date: March 6, 2003
    Inventors: Fabrice Vergne, Pierre Ducrot, Charles Andrianjara, Patrick Bernardelli, Edwige Lorthois
  • Modulators of peroxisome proliferator activated receptors
    Publication number: 20030045558
    Abstract: The present invention is directed to compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof, and methods of making, methods of using and pharmaceutical compositions having compounds represented by Structural Formula I and pharmaceutically acceptable salts, solvates and hydrates thereof: 1
    Type: Application
    Filed: April 11, 2002
    Publication date: March 6, 2003
    Applicant: Eli Lilly & Company Lily Corporate Center
    Inventors: Dawn A. Brooks, Christopher J. Rito, Anthony J. Shuker, Samuel J. Dominianni, Alan M. Warshawsky, Lynn S. Gossett, Donald P. Matthews, David A. Hay, Robert J. Ardecky, Pierre-Yves Michellys, John S. Tyhonas
  • Small-molecule modulators of hepatocyte growth factor / scatter factor activities
    Publication number: 20030045559
    Abstract: The invention is directed to small organic molecules having the ability to mimic or agonize hepatocyte growth factor/scatter factor (HGF/SF) activity, or inhibit or antagonize HGF/SF activity, the former useful for promoting, for example, vascularization of tissues or organs for promoting wound or tissue healing, or augmenting or restoring blood flow to ischemic tissues such as the heart following myocardial infarction. Inhibition of cellular growth or proliferation is beneficial in the treatment, for example, of inflammatory diseases such as inflammatory joint and skin diseases, and dysproliferative diseases such as cancer.
    Type: Application
    Filed: June 29, 2001
    Publication date: March 6, 2003
    Inventors: Sivaram Pillarisetti, Itzhak D. Goldberg
  • 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
    Publication number: 20030045560
    Abstract: This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: 1
    Type: Application
    Filed: June 13, 2002
    Publication date: March 6, 2003
    Applicant: Wyeth
    Inventors: Thomas Joseph Commons, Susan Christman Croce, Richard Page Woodworth, Eugene John Trybulski, Hassan Mohmoud Elokdah, David LeRoy Crandall
  • Method of treating isolated systolic hypertension
    Publication number: 20030045561
    Abstract: This invention relates to the use of eprosartan to treat isolated systolic hypertension.
    Type: Application
    Filed: September 19, 2002
    Publication date: March 6, 2003
    Applicant: SmithKline Beecham Corporation
    Inventors: David P. Brooks, Giora Z. Feuerstein, Eliot H. Ohlstein, Robert R. Ruffolo
  • Treatment of inflammatory, cancer, and thrombosis disorders
    Publication number: 20030045562
    Abstract: This invention provides for the treatment of inflammatory, cancer and thrombotic disorders through the administration, in combination, of a COX2 inhibitor, low dose aspirin, and antioxidant flavanoids, flavonoids or isoflavones and at least one of these combinations will be given in a subtherapeutic amount for improved anti-inflammatory, anti-cancer, and anti-thrombotic efficacy and safety.
    Type: Application
    Filed: August 30, 2001
    Publication date: March 6, 2003
    Inventors: Mawaheb M. EL-Naggar, Ahmed S. Mousa
  • Pharmaceutical composition having reduced tendency for drug crystallization
    Publication number: 20030045563
    Abstract: An orally deliverable pharmaceutical composition is provided comprising a drug of low water solubility, a solvent liquid that comprises at least one pharmaceutically acceptable solvent, and a turbidity-decreasing polymer, wherein (a) a substantial portion, for example at least about 15% by weight, of the drug is in dissolved or solubilized form in the solvent liquid, and (b) the polymer is present in an amount sufficient to substantially inhibit crystallization and/or precipitation of the drug in simulated gastric fluid.
    Type: Application
    Filed: January 15, 2002
    Publication date: March 6, 2003
    Inventors: Ping Gao, Michael J. Hageman, Walter Morozowich, Robert J. Dalga, Kevin J. Stefanski, Tiehua Huang, Aziz Karim, Fred Hassan, James C. Forbes
  • Saururus chinensis extract for prevention and treatment of neurodegenerative disease
    Publication number: 20030045564
    Abstract: The present invention relates to Saururus chinensis extract for prevention and treatment of neurodegenerative disease and pharmaceutical preparations containing Saururs chinensis extract or an aristolactam alkaloid derivative separated therefrom.
    Type: Application
    Filed: June 19, 2002
    Publication date: March 6, 2003
    Inventors: Young-Joong Kim, Sang-Hyun Sung, So-Ra Kim